Topfond Pharmaceutical Co., Ltd.
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference bad46fabe8
Drug names83First applicant · distinct drug namesAcceptance records137First applicant · distinct acceptance numbersUnder-review numbers30First applicant · current under-review listCo-applicant records4Subsequent applicant only · separate count
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/11 06:42.
Drug filings
137 acceptance records as first applicant, grouped into 83 source drug names. Source data as of 2026/11/11 06:42.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
No verified English name 2 records · Latest accepted 2026/10/26
Generic · 2
No verified English name 2 records · Latest accepted 2026/10/23
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2605310 | Supplement | 2026/10/23 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| CYZB2501927 | Supplement | 2025/09/05 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/10/23
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2605311 | Supplement | 2026/10/23 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| CYZB2501409 | Supplement | 2025/07/09 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/10/19
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2605202 | Supplement | 2026/10/19 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| CYZB2501346 | Supplement | 2025/07/01 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/10/19
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2605203 | Supplement | 2026/10/19 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| CYZB2501313 | Supplement | 2025/06/28 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/10/12
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2605097 | Supplement | 2026/10/12 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| CYZB2502333 | Supplement | 2025/10/17 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/10/12
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2605107 | Supplement | 2026/10/12 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| CYZB2501925 | Supplement | 2025/09/05 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
Tadalafil Tablets 4 records · Latest accepted 2026/09/21
Supplement · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2601781 | Supplement | 2026/09/21 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHB2601780 | Supplement | 2026/09/21 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHB2400183 | Supplement | 2024/02/02 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHB2400182 | Supplement | 2024/02/02 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
No verified English name 1 records · Latest accepted 2026/09/20
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2604856 | Supplement | 2026/09/20 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/09/08
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2604599 | Supplement | 2026/09/08 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| CYZB2502331 | Supplement | 2025/10/17 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/08/27
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2604378 | Supplement | 2026/08/27 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| CYZB2600756 | Supplement | 2026/03/06 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/08/27
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2604379 | Supplement | 2026/08/27 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| CYZB2502738 | Supplement | 2025/11/25 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/08/27
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2604374 | Supplement | 2026/08/27 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| CYZB2502367 | Supplement | 2025/10/22 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/08/27
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2604372 | Supplement | 2026/08/27 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| CYZB2501930 | Supplement | 2025/09/05 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 4 records · Latest accepted 2026/08/12
Supplement · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2601538 | Supplement | 2026/08/12 | Topfond Pharmaceutical Co., Ltd.; Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| CYHB2601537 | Supplement | 2026/08/12 | Topfond Pharmaceutical Co., Ltd.; Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| CYHB2600195 | Supplement | 2026/01/30 | Topfond Pharmaceutical Co., Ltd.; Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| CYHB2600194 | Supplement | 2026/01/30 | Topfond Pharmaceutical Co., Ltd.; Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanized | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/08/07
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2603953 | Supplement | 2026/08/07 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| CYZB2501396 | Supplement | 2025/07/09 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/08/07
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2603954 | Supplement | 2026/08/07 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| CYZB2501398 | Supplement | 2025/07/09 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/08/06
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2603935 | Supplement | 2026/08/06 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| CYZB2502836 | Supplement | 2025/12/02 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/08/06
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2603945 | Supplement | 2026/08/06 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| CYZB2502740 | Supplement | 2025/11/25 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/08/06
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2603936 | Supplement | 2026/08/06 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| CYZB2600759 | Supplement | 2026/03/06 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/08/06
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2603946 | Supplement | 2026/08/06 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| CYZB2502838 | Supplement | 2025/12/02 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
Sacubitril Valsartan Sodium Tablets 4 records · Latest accepted 2026/07/15
Supplement · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2601349 | Supplement | 2026/07/15 | Topfond Pharmaceutical Co., Ltd.; Jiangsu Vanguard Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHB2601348 | Supplement | 2026/07/15 | Topfond Pharmaceutical Co., Ltd.; Jiangsu Vanguard Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHB2401934 | Supplement | 2024/11/20 | Topfond Pharmaceutical Co., Ltd.; Jiangsu Vanguard Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHB2401933 | Supplement | 2024/11/20 | Topfond Pharmaceutical Co., Ltd.; Jiangsu Vanguard Pharmaceutical Co., Ltd. | CDE ↗ |
Tranexamic Acid Tablets 1 records · Latest accepted 2026/07/13
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2601322 | Supplement | 2026/07/13 | Topfond Pharmaceutical Co., Ltd.; Huayi Pharmaceuticals (Anhui) Co., Ltd. | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/07/10
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2603374 | Supplement | 2026/07/10 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| CYZB2502332 | Supplement | 2025/10/17 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/07/10
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2603375 | Supplement | 2026/07/10 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| CYZB2501926 | Supplement | 2025/09/05 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/06/22
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2602838 | Supplement | 2026/06/22 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| CYZB2502334 | Supplement | 2025/10/17 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
Bumetanide Injection 1 records · Latest accepted 2026/06/22
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2601167 | Supplement | 2026/06/22 | Topfond Pharmaceutical Co., Ltd.; Zhong Shan Wan Han Pharmaceutical Co., Ltd. romanized | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/06/22
Supplement · 2
Mirogabalin Besilate Tablets 3 records · Latest accepted 2026/06/11
Generic · 3
Pemafibrate Tablets 2 records · Latest accepted 2026/04/30
Generic · 2
Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets (Ⅰ) 2 records · Latest accepted 2026/04/28
Generic · 2
No verified English name 1 records · Latest accepted 2026/04/28
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2600994 | Generic | 2026/04/28 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/04/17
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2601495 | Supplement | 2026/04/17 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| CYZB2502739 | Supplement | 2025/11/25 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 1 records · Latest accepted 2026/04/17
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2601497 | Supplement | 2026/04/17 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 1 records · Latest accepted 2026/04/17
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2601496 | Supplement | 2026/04/17 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 1 records · Latest accepted 2026/03/06
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2600758 | Supplement | 2026/03/06 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 4 records · Latest accepted 2025/11/28
Generic · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2504096 | Generic | 2025/11/28 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHS2504095 | Generic | 2025/11/28 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHS2404505 | Generic | 2024/12/25 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHS2404504 | Generic | 2024/12/25 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/11/25
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2502392 | Supplement | 2025/11/25 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/11/06
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2502295 | Supplement | 2025/11/06 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
Apixaban Tablets 1 records · Latest accepted 2025/09/12
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2503371 | Generic | 2025/09/12 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/09/05
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2501771 | Supplement | 2025/09/05 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/09/05
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2501924 | Supplement | 2025/09/05 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/09/05
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2501929 | Supplement | 2025/09/05 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/09/03
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2501749 | Supplement | 2025/09/03 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/07/10
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2501429 | Supplement | 2025/07/10 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/07/05
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2501328 | Supplement | 2025/07/05 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/07/01
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2501347 | Supplement | 2025/07/01 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 2 records · Latest accepted 2025/06/28
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2501319 | Supplement | 2025/06/28 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| CYZB2501318 | Supplement | 2025/06/28 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/06/17
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2501195 | Supplement | 2025/06/17 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/06/17
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2501196 | Supplement | 2025/06/17 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
Diclofenac Sodium Enteric-coated Tablets 2 records · Latest accepted 2025/06/04
Supplement · 2
Dapagliflozin Tablets 2 records · Latest accepted 2025/05/24
Generic · 2
No verified English name 1 records · Latest accepted 2025/04/25
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2500784 | Supplement | 2025/04/25 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
No verified English name 1 records · Latest accepted 2024/12/17
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2402147 | Supplement | 2024/12/17 | Topfond Pharmaceutical Co., Ltd.; Shandong Lang Nuo Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Ibuprofen Tablets 2 records · Latest accepted 2024/11/01
Supplement · 2
No verified English name 1 records · Latest accepted 2024/09/25
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2450491 | Supplement | 2024/09/25 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
Clarithromycin Tablets 1 records · Latest accepted 2024/08/02
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2450415 | Supplement | 2024/08/02 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
Aspirin Enteric-coated Tablets 1 records · Latest accepted 2024/07/27
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2450410 | Supplement | 2024/07/27 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
Nicorandil for Injection 2 records · Latest accepted 2024/07/24
Generic · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2402329 | Generic | 2024/07/24 | Topfond Pharmaceutical Co., Ltd.; Hainan Tong Yong Kang Li Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| CYHS2402328 | Generic | 2024/07/24 | Topfond Pharmaceutical Co., Ltd.; Hainan Tong Yong Kang Li Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Lincomycin Injection 1 records · Latest accepted 2024/07/10
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2450368 | Supplement | 2024/07/10 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
Vonoprazan Fumarate Tablets 2 records · Latest accepted 2024/05/09
Generic · 2
Dabigatran Etexilate Capsules 2 records · Latest accepted 2024/05/06
Generic · 2
Clindamycin Injection 2 records · Latest accepted 2024/04/28
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2450259 | Supplement | 2024/04/28 | Topfond Pharmaceutical Co., Ltd.; Jin Yao Yong Guang (Hebei) Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| CYHB2450258 | Supplement | 2024/04/28 | Topfond Pharmaceutical Co., Ltd.; Jin Yao Yong Guang (Hebei) Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Nicorandil Tablets 1 records · Latest accepted 2024/04/13
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2450242 | Supplement | 2024/04/13 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
Urapidil Hydrochloride Injection 2 records · Latest accepted 2024/02/08
Generic · 2
Atomoxetine Hydrochloride Capsules 2 records · Latest accepted 2024/01/31
Supplement · 2
Clopidogrel Hydrogen Sulphate Tablets 1 records · Latest accepted 2024/01/29
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2400378 | Generic | 2024/01/29 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
Tranexamic Acid Injection 1 records · Latest accepted 2024/01/03
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2450004 | Supplement | 2024/01/03 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
Betahistine Dihydrochloride Tablets 2 records · Latest accepted 2023/10/31
Supplement · 2
Rivaroxaban Tablets 1 records · Latest accepted 2023/10/26
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2302365 | Supplement | 2023/10/26 | Topfond Pharmaceutical Co., Ltd.; Shanghai Pu Kang Pharma Co., Ltd. romanized | CDE ↗ |
Alprazolam Tablets 1 records · Latest accepted 2023/10/20
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2350773 | Supplement | 2023/10/20 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
Citicoline Sodium Injection 3 records · Latest accepted 2023/10/10
Supplement · 3
Oseltamivir Phosphate Capsules 1 records · Latest accepted 2023/09/23
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2302571 | Generic | 2023/09/23 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
No verified English name 1 records · Latest accepted 2023/08/01
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2302051 | Generic | 2023/08/01 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
Norepinephrine Bitartrate Injection 1 records · Latest accepted 2023/03/21
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2300854 | Generic | 2023/03/21 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
Argatroban Injection 1 records · Latest accepted 2023/01/13
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2340003 | Supplement | 2023/01/13 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
Telmisartan Tablets 1 records · Latest accepted 2022/11/04
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2250683 | Supplement | 2022/11/04 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
Metaraminol Tartrate Injection 1 records · Latest accepted 2022/08/18
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2201327 | Generic | 2022/08/18 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
Dapoxetine Hydrochloride Tablets 2 records · Latest accepted 2022/05/24
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2200770 | Supplement | 2022/05/24 | Topfond Pharmaceutical Co., Ltd.; Shenzhen Xin Li Tai Pharma Co., Ltd. romanized | CDE ↗ |
| CYHB2200771 | Supplement | 2022/05/11 | Topfond Pharmaceutical Co., Ltd.; Shenzhen Xin Li Tai Pharma Co., Ltd. romanized | CDE ↗ |
Febuxostat Tablets 2 records · Latest accepted 2022/05/11
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2200761 | Supplement | 2022/05/11 | Topfond Pharmaceutical Co., Ltd.; Nanjing Hai Na Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| CYHB2200760 | Supplement | 2022/05/11 | Topfond Pharmaceutical Co., Ltd.; Nanjing Hai Na Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Dexmedetomidine Hydrochloride Injection 1 records · Latest accepted 2021/11/11
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2102009 | Generic | 2021/11/11 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
Risedronate Sodium Tablets 1 records · Latest accepted 2021/01/30
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2150084 | Supplement | 2021/01/30 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
Metronidazole Tablets 1 records · Latest accepted 2021/01/05
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2050821 | Supplement | 2021/01/05 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
Changes in the last 90 days
28 events from 2026/08/14 to 2026/11/11. CDE data as of 2026/11/11 06:42; NMPA data as of 2026/11/10 18:31.
This source was last successfully updated at 2026/11/10 18:31; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Accepted: 16 applicationsNo longer listed under review: 6 applicationsSupplement delivery: 6 applications
- 2026/11/06No longer listed under review
No verified English name
CYZB2604856
Fact date: 2026/11/06 · Site observation date: 2026/11/06
Accepted: 2026/09/20
not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/11/06 (approval no.: —; approval date: 2026/11/04); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 172
NMPA · Table row 172 ↗ View source ↗ - 2026/11/06No longer listed under review
No verified English name
CYZB2603936
Fact date: 2026/11/06 · Site observation date: 2026/11/06
Accepted: 2026/08/06
not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/11/06 (approval no.: —; approval date: 2026/11/04); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 99
NMPA · Table row 99 ↗ View source ↗ - 2026/11/05No longer listed under review
No verified English name
CYZB2603945
Fact date: 2026/11/05 · Site observation date: 2026/11/05
Accepted: 2026/08/06
not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/11/04 (approval no.: —; approval date: 2026/11/03); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 38
NMPA · Table row 38 ↗ View source ↗ - 2026/11/04Supplement delivery
No verified English name
CYZB2604856
Fact date: 2026/11/04 · Publication date: 2026/11/06 · Site observation date: 2026/11/06
Supplemental application; excluded from new marketing approvals.
View source · Table row 172 ↗ - 2026/11/04Supplement delivery
No verified English name
CYZB2603936
Fact date: 2026/11/04 · Publication date: 2026/11/06 · Site observation date: 2026/11/06
Supplemental application; excluded from new marketing approvals.
View source · Table row 99 ↗ - 2026/11/04No longer listed under review
No verified English name
CYZB2603954
Fact date: 2026/11/04 · Site observation date: 2026/11/04
Accepted: 2026/08/07
not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/11/03 (approval no.: —; approval date: 2026/11/02); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 91
NMPA · Table row 91 ↗ View source ↗ - 2026/11/04No longer listed under review
No verified English name
CYZB2603953
Fact date: 2026/11/04 · Site observation date: 2026/11/04
Accepted: 2026/08/07
not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/11/03 (approval no.: —; approval date: 2026/11/02); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 90
NMPA · Table row 90 ↗ View source ↗ - 2026/11/04No longer listed under review
No verified English name
CYZB2603935
Fact date: 2026/11/04 · Site observation date: 2026/11/04
Accepted: 2026/08/06
not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/11/03 (approval no.: —; approval date: 2026/11/02); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 88
NMPA · Table row 88 ↗ View source ↗ - 2026/11/03Supplement delivery
No verified English name
CYZB2603945
Fact date: 2026/11/03 · Publication date: 2026/11/04 · Site observation date: 2026/11/04
Supplemental application; excluded from new marketing approvals.
View source · Table row 38 ↗ - 2026/11/02Supplement delivery
No verified English name
CYZB2603954
Fact date: 2026/11/02 · Publication date: 2026/11/03 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 91 ↗ - 2026/11/02Supplement delivery
No verified English name
CYZB2603953
Fact date: 2026/11/02 · Publication date: 2026/11/03 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 90 ↗ - 2026/11/02Supplement delivery
No verified English name
CYZB2603935
Fact date: 2026/11/02 · Publication date: 2026/11/03 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 88 ↗ - 2026/10/26Accepted
No verified English name
CYHS2602617
Fact date: 2026/10/26 · Site observation date: 2026/10/27
View source ↗ - 2026/10/26Accepted
No verified English name
CYHS2602616
Fact date: 2026/10/26 · Site observation date: 2026/10/27
View source ↗ - 2026/10/23Accepted
No verified English name
CYZB2605311
Fact date: 2026/10/23 · Site observation date: 2026/10/24
View source ↗ - 2026/10/23Accepted
No verified English name
CYZB2605310
Fact date: 2026/10/23 · Site observation date: 2026/10/24
View source ↗ - 2026/10/19Accepted
No verified English name
CYZB2605203
Fact date: 2026/10/19 · Site observation date: 2026/10/22
View source ↗ - 2026/10/19Accepted
No verified English name
CYZB2605202
Fact date: 2026/10/19 · Site observation date: 2026/10/22
View source ↗ - 2026/10/12Accepted
No verified English name
CYZB2605107
Fact date: 2026/10/12 · Site observation date: 2026/10/22
View source ↗ - 2026/10/12Accepted
No verified English name
CYZB2605097
Fact date: 2026/10/12 · Site observation date: 2026/10/22
View source ↗ - 2026/09/21Accepted
Tadalafil Tablets
CYHB2601781
Fact date: 2026/09/21 · Site observation date: 2026/10/22
View source ↗ - 2026/09/21Accepted
Tadalafil Tablets
CYHB2601780
Fact date: 2026/09/21 · Site observation date: 2026/10/22
View source ↗ - 2026/09/20Accepted
No verified English name
CYZB2604856
Fact date: 2026/09/20 · Site observation date: 2026/10/22
View source ↗ - 2026/09/08Accepted
No verified English name
CYZB2604599
Fact date: 2026/09/08 · Site observation date: 2026/10/22
View source ↗ - 2026/08/27Accepted
No verified English name
CYZB2604379
Fact date: 2026/08/27 · Site observation date: 2026/10/22
View source ↗ - 2026/08/27Accepted
No verified English name
CYZB2604378
Fact date: 2026/08/27 · Site observation date: 2026/10/22
View source ↗ - 2026/08/27Accepted
No verified English name
CYZB2604374
Fact date: 2026/08/27 · Site observation date: 2026/10/22
View source ↗ - 2026/08/27Accepted
No verified English name
CYZB2604372
Fact date: 2026/08/27 · Site observation date: 2026/10/22
View source ↗
Under review
30 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/11 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| No verified English name | CYHS2602617 | Generic | 2026/10/26 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| No verified English name | CYHS2602616 | Generic | 2026/10/26 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| No verified English name | CYZB2605311 | Supplement | 2026/10/23 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| No verified English name | CYZB2605310 | Supplement | 2026/10/23 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| No verified English name | CYZB2605203 | Supplement | 2026/10/19 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| No verified English name | CYZB2605202 | Supplement | 2026/10/19 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| No verified English name | CYZB2605107 | Supplement | 2026/10/12 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| No verified English name | CYZB2605097 | Supplement | 2026/10/12 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| Tadalafil Tablets | CYHB2601781 | Supplement | 2026/09/21 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| Tadalafil Tablets | CYHB2601780 | Supplement | 2026/09/21 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| No verified English name | CYZB2604599 | Supplement | 2026/09/08 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| No verified English name | CYZB2604379 | Supplement | 2026/08/27 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| No verified English name | CYZB2604378 | Supplement | 2026/08/27 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| No verified English name | CYZB2604374 | Supplement | 2026/08/27 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| No verified English name | CYZB2604372 | Supplement | 2026/08/27 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| No verified English name | CYHB2601538 | Supplement | 2026/08/12 | Topfond Pharmaceutical Co., Ltd.; Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | CYHB2601537 | Supplement | 2026/08/12 | Topfond Pharmaceutical Co., Ltd.; Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | CYZB2603946 | Supplement | 2026/08/06 | Topfond Pharmaceutical Co., Ltd.; Henan Tian Fang Pharma Zhong Yao Co., Ltd. romanized | CDE ↗ |
| Mirogabalin Besilate Tablets | CYHS2601386 | Generic | 2026/06/11 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| Mirogabalin Besilate Tablets | CYHS2601385 | Generic | 2026/06/11 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| Mirogabalin Besilate Tablets | CYHS2601383 | Generic | 2026/06/11 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| Pemafibrate Tablets | CYHS2601005 | Generic | 2026/04/30 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets (Ⅰ) | CYHS2600996 | Generic | 2026/04/28 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| No verified English name | CYHS2600994 | Generic | 2026/04/28 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets (Ⅰ) | CYHS2600993 | Generic | 2026/04/28 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| No verified English name | CYHS2504096 | Generic | 2025/11/28 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| No verified English name | CYHS2504095 | Generic | 2025/11/28 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| Apixaban Tablets | CYHS2503371 | Generic | 2025/09/12 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| Dapagliflozin Tablets | CYHS2501871 | Generic | 2025/05/24 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| Dapagliflozin Tablets | CYHS2501870 | Generic | 2025/05/24 | Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
Catalogue holder records
60 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/11 06:38. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Diclofenac Sodium Enteric-coated Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H41020487 | 2026/06/12 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Nicorandil for Injection | Topfond Pharmaceutical Co., Ltd. | Hainan Tong Yong San Yang Pharma Co., Ltd. romanized | 国药准字H20263979 | 2026/04/14 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Nicorandil for Injection | Topfond Pharmaceutical Co., Ltd. | Hainan Tong Yong San Yang Pharma Co., Ltd. romanized | 国药准字H20263980 | 2026/04/14 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Vonoprazan Fumarate Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20263329 | 2026/02/02 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Vonoprazan Fumarate Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20263330 | 2026/02/02 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Dabigatran Etexilate Capsules | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20263199 | 2026/01/27 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Dabigatran Etexilate Capsules | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20263200 | 2026/01/27 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Dabigatran Etexilate Capsules | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20263199 | 2026/01/27 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Ibuprofen Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H41021548 | 2026/01/08 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Ibuprofen Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H41021547 | 2026/01/08 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Clarithromycin Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20046141 | 2025/12/25 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Shandong Lang Nuo Pharmaceutical Co., Ltd. romanized | 国药准字H20256277 | 2025/12/16 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20258226 | 2025/10/17 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Lincomycin Injection | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H41020128 | 2025/09/17 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Aspirin Enteric-coated Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20258162 | 2025/08/18 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Tadalafil Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字 H20258132 | 2025/07/18 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Tadalafil Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字 H20258130 | 2025/07/18 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20254784 | 2025/07/08 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Clindamycin Injection | Topfond Pharmaceutical Co., Ltd. | Jin Yao Yong Guang (Hebei) Pharmaceutical Co., Ltd. romanized | 国药准字H10980089 | 2025/07/02 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Clindamycin Injection | Topfond Pharmaceutical Co., Ltd. | Jin Yao Yong Guang (Hebei) Pharmaceutical Co., Ltd. romanized | 国药准字H20030110 | 2025/07/02 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Urapidil Hydrochloride Injection | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20254701 | 2025/06/30 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Urapidil Hydrochloride Injection | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20254700 | 2025/06/30 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Clopidogrel Hydrogen Sulphate Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20254305 | 2025/05/27 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Tranexamic Acid Injection | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20258023 | 2025/03/05 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Sacubitril Valsartan Sodium Tablets | Topfond Pharmaceutical Co., Ltd. | Jiangsu Vanguard Pharmaceutical Co., Ltd. | 国药准字H20253444 | 2025/02/25 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Sacubitril Valsartan Sodium Tablets | Topfond Pharmaceutical Co., Ltd. | Jiangsu Vanguard Pharmaceutical Co., Ltd. | 国药准字H20253445 | 2025/02/25 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Nicorandil Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H41024517 | 2024/12/18 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Oseltamivir Phosphate Capsules | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20249545 | 2024/12/01 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Atomoxetine Hydrochloride Capsules | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20247297 | 2024/11/28 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Atomoxetine Hydrochloride Capsules | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20120098 | 2024/11/28 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Citicoline Sodium Injection | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20033469 | 2024/11/27 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Citicoline Sodium Injection | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H41025001 | 2024/11/27 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Citicoline Sodium Injection | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H19993470 | 2024/11/27 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Norepinephrine Bitartrate Injection | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20249334 | 2024/11/15 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Alprazolam Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H41020272 | 2024/10/22 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Betahistine Dihydrochloride Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20247121 | 2024/06/05 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Betahistine Dihydrochloride Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H41023572 | 2024/06/05 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Metaraminol Tartrate Injection | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20243350 | 2024/03/19 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Argatroban Injection | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20223717 | 2024/02/06 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Telmisartan Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20041746 | 2023/11/10 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H41020479 | 2023/10/09 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Dexmedetomidine Hydrochloride Injection | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20234057 | 2023/08/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Metronidazole Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H41020125 | 2022/10/14 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Tadalafil Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20223604 | 2022/08/23 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Atropine Sulfate Injection | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H41020291 | 2022/08/01 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Levetiracetam Concentrated Solution for Injection | Topfond Pharmaceutical Co., Ltd. | Jiangsu Shen Long Pharma Co., Ltd. romanized | 国药准字H20223176 | 2022/03/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20223159 | 2022/03/22 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20223160 | 2022/03/22 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Risedronate Sodium Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20051021 | 2022/02/25 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Captopril Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H41021572 | 2022/01/24 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Captopril Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H41021571 | 2022/01/24 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Nateglinide Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20041609 | 2022/01/06 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Azithromycin Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20044687 | 2021/11/22 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Thioctic Acid Injection | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20213741 | 2021/09/24 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Thioctic Acid Injection | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20213740 | 2021/09/24 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H41021588 | 2021/04/20 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Nateglinide Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20058909 | 2021/03/08 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Nateglinide Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20058910 | 2021/03/08 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Atorvastatin Calcium Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20203378 | 2020/07/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Atorvastatin Calcium Tablets | Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20203379 | 2020/07/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
80 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/11 06:40.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20260000662 | I | 2026/08/17 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20260000097 | I | 2026/02/09 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20250000457 | I | 2025/05/27 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20250000241 | I | 2025/05/19 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20250000248 | I | 2025/04/02 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20240001466 | A | 2026/06/04 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20240001567 | A | 2026/07/14 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20240000112 | A | 2026/06/24 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20230001371 | A | 2026/06/06 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20230001028 | A | 2025/07/06 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20230001027 | A | 2025/03/21 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20230001079 | A | 2025/10/22 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20220001149 | A | 2025/05/20 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20220000891 | A | 2025/03/04 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20220000727 | A | 2026/05/20 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20220000649 | A | 2024/04/16 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20220000107 | A | 2025/04/02 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20210001160 | A | 2023/12/21 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20210000843 | A | 2023/09/06 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20200001443 | A | 2025/06/19 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20200001441 | A | 2022/08/31 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190000845 | A | 2026/07/17 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20200000075 | A | 2025/12/31 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190021551 | A | 2025/09/04 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190021252 | A | 2022/08/15 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190009891 | A | 2024/03/19 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190009879 | A | 2023/12/19 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190008932 | A | — | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190008300 | A | 2025/12/17 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190008299 | A | 2025/06/19 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190008235 | A | 2025/08/27 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190008212 | A | 2025/08/22 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190007867 | A | 2026/02/03 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190007695 | A | 2025/07/29 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190007651 | A | 2024/05/09 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190007460 | A | — | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190007443 | A | 2023/12/28 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190007441 | A | 2025/08/27 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190007440 | A | 2024/01/17 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190007439 | A | 2025/06/19 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190007438 | A | 2024/11/01 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190007412 | A | 2024/01/17 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190007411 | A | — | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190007410 | A | 2025/08/17 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190007409 | A | — | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190007408 | A | 2026/08/18 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190007405 | A | 2023/12/19 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190006750 | A | 2025/08/22 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190006749 | A | 2025/08/22 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190006710 | A | 2025/08/23 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190006709 | A | 2025/08/22 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190006317 | A | 2024/11/01 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190003485 | A | — | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190003481 | A | — | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190003479 | A | 2024/09/11 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190003045 | A | — | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190003042 | A | — | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190003039 | A | 2024/08/27 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190003038 | A | — | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190003037 | A | 2025/08/27 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190003036 | A | — | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190003035 | A | — | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190003034 | A | — | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190003031 | A | — | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190003030 | A | — | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190003029 | A | — | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190003027 | A | — | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190003025 | A | — | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190001667 | A | — | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190001666 | A | 2025/07/29 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190001665 | A | — | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190001664 | A | — | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190001663 | A | 2023/12/28 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190000454 | I | 2019/06/12 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20180000232 | I | 2019/01/14 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20170001387 | A | 2026/02/25 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20170000640 | A | 2026/04/30 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20170000541 | A | 2025/02/06 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20170000390 | A | 2024/12/19 | CDE ↗ |
| No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20170000302 | I | — | CDE ↗ |
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
4 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/11 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Dapagliflozin Tablets | CYHB2601145 | Supplement | 2026/06/17 | Ren Xi Pharmaceuticals Technology Hebei Co., Ltd. romanized; Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| Dapagliflozin Tablets | CYHS2403161 | Generic | 2024/09/25 | Ren Xi Pharmaceuticals Technology Hebei Co., Ltd. romanized; Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| Citicoline Injection | CYHS2201408 | Generic | 2022/08/29 | Hubei Shen Zhou Hua Rui Pharmaceuticals Co., Ltd. romanized; Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
| Citicoline Injection | CYHS2201407 | Generic | 2022/08/29 | Hubei Shen Zhou Hua Rui Pharmaceuticals Co., Ltd. romanized; Topfond Pharmaceutical Co., Ltd. | CDE ↗ |
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/11 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/11 06:38
- Full API register
- Last successful update: 2026/11/11 06:40
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31 · Current coverage may be incomplete
First index-page publication dates: — to —; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Drug names use verified official English names only. Missing names are shown as No verified English name, linking to a Chinese page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized. Original statutory reference numbers are the sole visible Chinese exception.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Chinese free text is not displayed; use the source links or source-name columns in CSV exports.